Insulet Corporation
HealthcareNASDAQ:PODD · NASDAQ Global Select
+$0.51 today
Vol 0.98M · Avg 1.34M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
16.3%
avg -16.1%
ROIC
13.6%
avg 2.1%
ROA
7.7%
avg -0.4%
Analysis
ROE is currently the strongest return metric at 16.3% versus its period average of -16.1%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ashley A. McEvoy | Chief Executive Officer, President & Director | $3.14M | — | 55 | $22,551.00 | 0.03% |
Eric Benjamin | Executive Vice President & Chief Operating Officer | $1.52M | — | 43 | $23,868.00 | 0.03% |
Flavia H. Pease | Executive Vice President & Chief Financial Officer | $1.45M | — | 53 | $19,159.00 | 0.03% |
John Wodick Kapples | Senior Vice President & General Counsel | $1.17M | — | 66 | $27,708.00 | 0.04% |
Prem Singh | Senior Vice President of Global Operations | $992,670.00 | — | 49 | $6,891.00 | <0.01% |
Amit Guliani | Senior Vice President & Chief Technology Officer | $954,141.00 | — | — | — | — |
Chuck Medovich | Senior VP and Chief Quality, Regulatory & Compliance Officer | — | — | — | — | — |
Philip Hildale | Senior Vice President of Sales & Customer Care | — | — | — | — | — |
Angela Geryak Wiczek | Senior Director of Corporate Communications | — | — | — | — | — |
Clare Trachtman | Vice President of Investor Relations | — | — | — | — | — |
Laetitia Cousin | Senior Vice President of Regulatory Affairs, Quality Assurance & Compliance | — | — | 50 | $5,727.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$2.23M
Sells
8
$4.05M
Net Sentiment
$1.82M
Net selling
Most Active
Singh Prem
3 transactions
1–10 of 12
Analysis
Insiders reported 4 buys worth $2.23M and 8 sells worth $4.05M over the last 12 months. That adds up to net selling of $1.82M. Singh Prem was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +7.7% | +23.3% (15yr)9 analysts |
| Net Income | N/A | N/A | N/A | N/A9 analysts |
| EBIT | N/A | N/A | N/A | N/A9 analysts |
Analysis
Recent growth has been strongest in Revenue at +7.7% over three years. Forward estimates point to Revenue at +23.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Biogen Inc.
NASDAQ:BIIB
$29.53B
DexCom, Inc.
NASDAQ:DXCM
$29.08B
Koninklijke Philips N.V.
NYSE:PHG
$25.70B
West Pharmaceutical Services, Inc.
NYSE:WST
$23.23B
Waters Corporation
NYSE:WAT
$23.17B
Quest Diagnostics Incorporated
NYSE:DGX
$22.48B
Labcorp Holdings Inc.
NYSE:LH
$21.83B
STERIS plc
NYSE:STE
$20.26B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.13B
Smith & Nephew plc
NYSE:SNN
$12.97B
Who manages PODD?
Insulet Corporation (PODD) lists 11 active executives. The top listed executive is Eric Benjamin, Executive Vice President & Chief Operating Officer.
Are PODD insiders buying or selling?
Recent insider activity shows net buying of $9.08M.
Explore More
Continue the stock analysis
Jump to another research area for this company.